Article Highlights CanREValue Collaboration for RWE
January 9, 2020
A recent article published in BMJ highlights efforts by the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration, which aims to develop a framework for real-world evidence evaluation and integration.
According to the article, CanREValue has deployed five RWE working groups: Planning and Drug Selection, Methods, Data, Reassessment and Uptake, and Engagement.
” … The CanREValue collaboration is bringing together key stakeholders from across the system and country to develop clear guidance, methods and processes for how RWE could be generated and used to support cancer drug funding decision-making in Canada,” the authors write.
To read the article on BMJ, click here.
